Despite a 22 percent decline in Biogen Inc.’s fourth-quarter income, attributable mostly to its recent settlement with Forward Pharma A/S, company shares (NASDAQ:BIIB) climbed 2 percent to $278.89 on Thursday after the company delivered 2017 guidance largely in line with analyst expectations and news that its launch of spinal muscular atrophy (SMA) drug Spinraza (nusinersen) was progressing, though more slowly than hoped amid insurer pushback.